- Market Capitalization, $K 338,221
- Shares Outstanding, K 47,704
- Annual Sales, $ 106,480 K
- Annual Income, $ -126,790 K
- 60-Month Beta 1.01
- Price/Sales 3.18
- Price/Cash Flow N/A
- Price/Book 1.01
|Period||Period Low||Period High||Performance|
| || |
-1.83 (-20.52%)since 08/22/23
| || |
-4.05 (-36.36%)since 06/22/23
| || |
-10.50 (-59.69%)since 09/22/22
The company is facing being delisted from the S&P 600 Index.
UniQure: Q2 Earnings Snapshot
An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors.
Investors are focusing on the negative parts of the biotech company's interim results.
The S&P 500 Index ( $SPX ) ( SPY ) is up +0.09%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is up +0.01%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is up +0.35%. U.S. stock index futures this morning...
uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
UniQure: Q1 Earnings Snapshot
Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.
uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA)...
|Advisorshares Alpha Dna Equity Sentiment ETF|
|Invesco Nasdaq Future Gen 200 ETF|
|S&P Biotech SPDR|
|Xt S&P Smallcap 600 ESG ETF|
|Virtus Lifesci Biotech Clinical Trials ETF|